Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Phase II study shows eltrombopag efficacy in HCV-associated thrombocytopenia

Oct. 31, 2006

New agents for obesity and other metabolic disorders imparted in recent patents

Oct. 30, 2006

Locomogene begins research collaboration on obesity drug with Kyushu University

Oct. 30, 2006

Diabetes drug KB-3305 cleared to begin clinical testing

Oct. 30, 2006

Amylin to study neurohormones used in combination to treat obesity

Oct. 27, 2006

ABT-279: Abbott's new selective and safe DPP-IV inhibitor

Oct. 27, 2006

Alantos and Servier collaborate on DPP-IV inhibitor ALS-2-0426

Oct. 26, 2006

Preliminary three-month findings from endometriosis study of Proellex

Oct. 26, 2006

Recent patents cover possible novel treatment options for diabetes and associated disorders

Oct. 25, 2006

Data on phenylalanine reduction with sapropterin reported

Oct. 25, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...